Scarica l'app Stockscreener
2.12
8.72%
0.17
Dopo l'orario di chiusura:
2.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMEA Giù?
Forum
Previsione
Precedente Chiudi:
$1.95
Aprire:
$1.89
Volume 24 ore:
735.61K
Relative Volume:
1.14
Capitalizzazione di mercato:
$79.65M
Reddito:
-
Utile/perdita netta:
$-144.01M
Rapporto P/E:
-0.5287
EPS:
-4.01
Flusso di cassa netto:
$-113.02M
1 W Prestazione:
-7.83%
1M Prestazione:
-23.19%
6M Prestazione:
-79.77%
1 anno Prestazione:
-83.18%
Intervallo 1D:
$1.86
$2.13
Intervallo di 1 settimana:
$1.86
$2.29
Portata 52W:
$1.86
$13.66
Biomea Fusion Inc Stock (BMEA) Company Profile
Nome
Biomea Fusion Inc
Settore
Industria
Telefono
(650) 980-9099
Indirizzo
900 MIDDLEFIELD ROAD, REDWOOD CITY
Confronta BMEA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
2.12 | 79.65M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-09 | Iniziato | Edward Jones | Buy |
| 2024-09-27 | Aggiornamento | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | Aggiornamento | Truist | Hold → Buy |
| 2024-08-29 | Iniziato | CapitalOne | Overweight |
| 2024-06-11 | Downgrade | Truist | Buy → Hold |
| 2024-06-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-04-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-06 | Iniziato | Truist | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-06-26 | Downgrade | Jefferies | Buy → Hold |
| 2023-05-12 | Iniziato | Barclays | Overweight |
| 2023-03-29 | Reiterato | Oppenheimer | Outperform |
| 2023-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2023-02-24 | Iniziato | Citigroup | Buy |
| 2022-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-12 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-05-11 | Iniziato | JP Morgan | Overweight |
| 2021-05-11 | Iniziato | Jefferies | Buy |
| 2021-05-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Biomea Fusion Inc Borsa (BMEA) Ultime notizie
Biomea Fusion stock hits 52-week low at $1.86 amid sharp decline - Investing.com India
Biomea Fusion stock hits 52-week low at $1.86 amid sharp decline By Investing.com - Investing.com South Africa
HC Wainwright Reduces Earnings Estimates for Biomea Fusion - Defense World
Barclays Issues Pessimistic Forecast for Biomea Fusion (NASDAQ:BMEA) Stock Price - Defense World
HC Wainwright Weighs in on Biomea Fusion Q1 Earnings - Defense World
After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA) - Yahoo Finance
Biomea Fusion’s Strategic Shift: A Year of Transformation - TipRanks
Biomea Fusion, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biomea Fusion Expands Team with Strategic Equity Compensation Package - Stock Titan
After Plunging -19.32% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA) - Yahoo Finance
Biomea Fusion Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Biomea Fusion (NASDAQ:BMEA) Receives “Buy” Rating from HC Wainwright - Defense World
Biomea Fusion reports Q4 EPS (81c), consensus (93c) - TipRanks
Biomea Fusion, Inc. SEC 10-K Report - TradingView
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - The Manila Times
Breakthrough: Biomea's Diabetes Treatment Achieves Major Blood Sugar Control Milestone - Stock Titan
After Plunging -20.42% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA) - Yahoo Finance
Virtu Financial LLC Makes New Investment in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
Biomea Fusion (BMEA) to Release Earnings on Monday - Defense World
BIOMEA FUSION Earnings Preview: Recent $BMEA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Biomea Fusion Inc expected to post a loss of 92 cents a shareEarnings Preview - TradingView
Biomea Fusion stock hits 52-week low at $2.33 amid sharp decline By Investing.com - Investing.com South Africa
Biomea Fusion stock hits 52-week low at $2.33 amid sharp decline - Investing.com Australia
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of “Buy” by Brokerages - Defense World
Thomas Butler steps down as Biomea CEO - biocentury.com
Biomea Fusion Appoints Michael Hitchcock Interim CEO - MarketScreener
Biomea Fusion appoints Mick Hitchcock to succeed Thomas Butler as interim CEO - Seeking Alpha
Biomea Fusion’s SWOT analysis: stock’s potential amid clinical trials By Investing.com - Investing.com Australia
Biomea Fusion names Mick Hitchcock to succeed Thomas Butler as interim CEO - TipRanks
Biomea Fusion Announces Leadership Transition - GlobeNewswire
Former Gilead Sciences VP Named CEO as Biomea Advances Breakthrough Diabetes Drug - Stock Titan
Strategy (MSTR) Executives Buy Company’s Preferred Stock - The Globe and Mail
Stocks in play: Trilogy Metals Inc. - The Globe and Mail
Biomea Fusion’s SWOT analysis: stock’s potential amid clinical trials - Investing.com India
Biomea Fusion announces presentation of icovamenib preclinical, clinical data - Yahoo Finance
Biomea Fusion Presents Promising Clinical Data on Icovamenib at ATTD 2025, Highlighting Its Potential as a Disease-Modifying Therapy for Type 2 Diabetes - Nasdaq
Icovamenib Treatment in Patients with Severe - GlobeNewswire
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose - Yahoo Finance
Investors who Lost Money on Biomea Fusion, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationBMEA - ACCESS Newswire
Biomea Fusion Insiders Recover Some Losses, Which Stand At US$91k - Yahoo
D. Boral Capital Reiterates “Buy” Rating for Biomea Fusion (NASDAQ:BMEA) - Defense World
Biomea Fusion stock hits 52-week low at $2.49 amid sharp decline - Investing.com
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Biomea Fusion, Inc. (BMEA) - accessnewswire.com
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biomea Fusion reports inducement grant under Nasdaq listing rule - TipRanks
How Biomea Fusion's Latest Employee Stock Grant Reflects Its Talent Acquisition Strategy - StockTitan
An Investigation Has Commenced on Behalf of Biomea Fusion, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your BMEA Losses - ACCESS Newswire
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Biomea Fusion CFO Franco Valle Resigns - TipRanks
Biomea Fusion Inc Azioni (BMEA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):